Cagrilintide mimics amylin for added fullness signaling
Disclosure of interest: none Poster Session II - RISK FACTORS - PRIMARY AND SECONDAR PREVENTION 05.00 - RISK FACTORS AND PREVENTION (PRIMARY AND SECONDARY) - 05.02 - SECONDARY PREVENTION P1002 - ESOC25-228 PREDIABETES AND DIABETES MELLITUS TYPE 2 ONE YEAR AFTER ACUTE ISCHEMIC STROKE Kurt Mlgg 1,2 , Anel Karisik 1,2 , Lukas Scherer 1,2 , Lucie Buergi 1,2 , Benjamin Dejakum 1 , Silvia Komarek 1 , Julian Granna 2 , Christian Boehme 1 , Raimund Pechlaner 1 , Thomas Tll 1 , Michael Knoflach, Stefan Kiechl 1,2 , Susanne Kaser 3 , Alexander Egger 4 , Andrea Griesmacher 4 , Lukas Mayer-Suess 1 1 Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria, 2 VASCage, Centre on Clinical Stroke Research, Innsbruck, Austria, 3 Department of Internal Medicine I, Medical University of Innsbruck, Innsbruck, Austria, 4 Central Institute of Clinical Chemistry and Laboratory Medicine, Medical University of Innsbruck, Innsbruck, Austria Background and Aims: The evolution of glycemic status in post-stroke patients remains poorly understood, particularly regarding treatments for type II diabetes mellitus (DM II), such as glucagon-like peptide-1 receptor agonists (GLP-1-RA) and sodium-glucose co-transporter 2 (SGLT-2) inhibitors, which have not been studied in an exclusive post-stroke population
After 30 days on the 1.5 mg dose, increase the dose to 4 mg once daily
Why is BPC-157 sold online if its not legal
As research progresses, Dihexa may pave the way for novel therapeutic interventions to improve outcomes and quality of life for patients with spinal cord injury and nerve damage
